CompletedNCT02429518

Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Knight Therapeutics (USA) Inc
Principal Investigator
Jaime Soto, MD
Fundacion Nacional de Dermatologia
Intervention
Miltefosine(drug)
Enrollment
42 target
Eligibility
18-55 years · All sexes
Timeline
20152018

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02429518 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis

← Back to all trials